Status:
WITHDRAWN
Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
COVID19
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
A controlled trial of the drug tranexamic acid (TXA) in inpatients recently admitted to the hospital with the diagnosis of COVID19. It is hypothesized that TXA will reduce the infectivity and virulenc...
Detailed Description
A recent report in Physiological Reviews proposed that the endogenous protease plasmin acts on COVID19 virus by cleaving a newly inserted furin site in the S protein portion of the virus resulting in ...
Eligibility Criteria
Inclusion
- Positive COVID19 test
- Admission to hospital without immediate plans for Intensive Care Unit transfer
- Age \>/= 19 y.o.
Exclusion
- Allergic reaction to tranexamic acid
- History or active evidence of hypercoagulation disorders including but not limited to deep vein thrombosis, pulmonary hypertension, diffuse intravascular coagulopathy
- Preadmission anticoagulation
- History of GI bleeding
- History of seizures
- Cardiac or other vascular stents
- History of severe renal disease
- History of intracranial hemorrhage
Key Trial Info
Start Date :
September 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04338126
Start Date
September 30 2021
End Date
December 31 2021
Last Update
April 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233